Shots:

• Alexion to initiate a cash tender offer to acquire all of the issued & outstanding shares of LogicBio's common stock for $0.0001 par value/share at a purchase price of $2.07/share representing a 660% premium for $68M. The transaction is expected to be close in 4 to 6wks. 
• The acquisition advances Alexion’s growth in genomic medicines through LogicBio’s technology, experienced rare disease R&D team, and expertise in pre-clinical development. LogicBio is developing gene-editing therapies to treat a pediatric rare disease
• GeneRid, developed by LogicBio is a novel method for precise gene insertion that makes use of a cell's inherent DNA repair mechanism to achieve long-lasting therapeutic protein expression levels

Ref: Businesswire | Image: Alexion